MAPK6 and lung carcinoma: Another study showed that ERK3 increased the chemoresistance of lung cancer cells to topoisomerase II inhibitors, such as etoposide, teniposide and doxorubicin, which induce DNA damage and apoptosis and are widely used as anti-cancer therapeutics [62,63].